Neurogene (NASDAQ:NGNE) Price Target Raised to $70.00 at HC Wainwright

Neurogene (NASDAQ:NGNE) had its price target lifted by HC Wainwright from $65.00 to $70.00 in a research note published on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Neurogene presently has a consensus rating of “Hold” and a consensus target price of $42.50.

Neurogene Stock Down 14.8%

Neurogene stock opened at $26.49 on Thursday. The stock has a market cap of $378.07 million, a price-to-earnings ratio of -6.15 and a beta of 1.64. The business has a 50-day simple moving average of $25.22 and a 200 day simple moving average of $21.30. Neurogene has a 52 week low of $6.88 and a 52 week high of $43.24.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.27. On average, research analysts anticipate that Neurogene will post -4.27 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Baker BROS. Advisors LP boosted its position in Neurogene by 120.4% during the first quarter. Baker BROS. Advisors LP now owns 1,486,200 shares of the company’s stock valued at $17,403,000 after buying an additional 811,750 shares during the period. Blair William & Co. IL increased its holdings in shares of Neurogene by 141.3% in the first quarter. Blair William & Co. IL now owns 151,180 shares of the company’s stock worth $1,770,000 after buying an additional 88,540 shares during the period. Jennison Associates LLC lifted its stake in shares of Neurogene by 55.0% in the 2nd quarter. Jennison Associates LLC now owns 167,563 shares of the company’s stock valued at $2,505,000 after acquiring an additional 59,479 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Neurogene by 81.6% in the 2nd quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock valued at $1,426,000 after acquiring an additional 42,880 shares during the last quarter. Finally, Schroder Investment Management Group purchased a new stake in Neurogene during the 2nd quarter valued at about $451,000. 52.37% of the stock is currently owned by institutional investors.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.